Symphogen A/S and Open Monoclonal Technology, Inc. (OMT) have announced an alliance that provides Symphogen with unlimited access to OMT’s OmniRat® and OmniMouse® platforms.
Symphogen will use its proprietary B cell-based antibody identification technology, Symplex™, and access the diverse immune repertoires generated in OMT’s transgenic animals to develop novel human therapeutic candidates.
“OMT’s complementary transgenic animals for generation of fully human antibodies fit well with our long-standing strategy of using wild type mice and chickens and even humans as sources of rare, highly diverse antibodies,” said Ivan Horak, Chief Scientific & Medical Officer at Symphogen.
“With the success of our antibody mixture approach our need for high quality antibodies has expanded and OMT’s transgenic animals will enable us to more rapidly create new multi-antibody product candidates,” said Horak.
Dr. Roland Buelow, founder and CEO of OMT, continued, “Symphogen has demonstrated the therapeutic value of antibody cocktail approaches and the need for antibody diversity that targets unique epitopes. OmniRat is well proven, published and partnered. OmniMouse provides additional epitope coverage and the combined platforms will enable Symphogen to establish superior antibody cocktail products. This unlimited access, multi-platform partnership illustrates how OMT also adds value to rapidly growing, mid-size companies, which is an important element in OMT’s pursuit to make OmniRat and OmniMouse preferred brands in human therapeutic antibody discovery.”